Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ADEROLIO 0,25 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ADEROLIO 0,25 MG COMPRIMIDOS EFG

Approved

STANDARD

ADEROLIO 0,25 MG COMPRIMIDOS EFG

Sandoz Farmaceutica S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 22, 2023
Approval ID: 52ea49a1ad68a7ba
Company: Sandoz Farmaceutica S.A.
Type: Standard

Approval Details

Approval Id: 52ea49a1ad68a7ba
Drug Cima Aemps Name: ADEROLIO 0,25 MG COMPRIMIDOS EFG
Register Number: 88846
Holder Company Name: Sandoz Farmaceutica S.A.
Marketing Company Name: Sandoz Farmaceutica S.A.
Authorization Date: 2023-05-22
Dosage Form: COMPRIMIDO
Dose: 0,25 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Sandoz Farmaceutica S.A.

Active Ingredients

EVEROLIMUS

0,25 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 22, 2023

Approval ID

52ea49a1ad68a7ba

Type

Standard

Back to CIMA-AEMPS Approvals